Internalize your next-gen sequencing Anthology Diagnostics Co-Op

GTC Partners

Genomic Testing Cooperative’s and Anthology Diagnostics Cooperative Model 

Anthology Diagnostics is the first lab to utilize GTC’s cooperative business model to internalize their next-gen sequencing testing for oncology analyzing DNA and RNA. Anthology Diagnostics was opened with the vision of providing comprehensive genomic profiling to the Hackensack Meridian Health cancer patient population; and to serve physicians and labs within the greater NJ area. 

Learn how you can internalize your NGS testing for oncology

The cooperative business model allows labs to share resources, best practices, data and help each other with publications studies. The goal is to provide a more collaborative business model, drive down the cost of testing and improve quality/standardization of testing. 

Both labs offer standardized comprehensive genomic profiling covering both solid tumors and hematologic neoplasms, including a robust liquid biopsy option. 


In addition, GTC supports labs looking to internalize NGS and helps by providing:

  • Necessary instruments and reagents
  • Reference materials
  • Validations
  • Training
  • SOP’s
  • Medical expertise
  • Research and development
  • New product pipeline
  • Other tools

What sets the solution apart is:

  • Next-gen sequencing of both DNA and RNA
  • The RNA looks at fusions, gene expression, alternative splicing and clinical prediction
  • AI/Machine learning informatics tools for interpretation
  • Data sharing
  • Joint publication opportunities
  • Purchasing power
  • Research and development
  • Medicare coverage
Anthology Diagmostics
Samples from each lab would have identical results reports with info on detected genomic alterations with reference levels, tumor heterogeneity, expression levels, therapeutic recommendations and clinical trial options

Patients who undergo testing will be given a precision diagnosis of their disease and subclassification. They will be given the best chance to be matched to a precision medicine based on their tumor’s signature or enrolled in a clinical trial. Most importantly patients will be contributing to the knowledge base of cancer to help everyone who gets a cancer diagnosis

Inquire about CoOp Model